Nuclear medicine

INTERNATIONAL ISOTOPES INC. ANNOUNCES FISCAL RESULTS FOR FISCAL YEAR 2023

Retrieved on: 
Monday, April 1, 2024
Medical device, Thyroid cancer, Growth, The Twelve Months, Third party, Calibration, Sale, IDAHO, Intellectual property, I-131, OTCQB, Nuclear medicine, Cryptocurrency

IDAHO FALLS, Idaho, April 1, 2024 /PRNewswire/ -- International Isotopes Inc. (OTCQB: INIS) (the "Company" or "INIS") announces its financial results for the twelve-month periods ended December 31, 2023.

Key Points: 
  • IDAHO FALLS, Idaho, April 1, 2024 /PRNewswire/ -- International Isotopes Inc. (OTCQB: INIS) (the "Company" or "INIS") announces its financial results for the twelve-month periods ended December 31, 2023.
  • Revenue for the twelve months ended December 31, 2023, was $12.3 million compared to $11.2 million for the same period in 2022.
  • As of December 31, 2023, cash and cash equivalents improved to $2.7 million compared to $2.4 million as of December 31, 2022.
  • Shahe Bagerdjian, President & CEO of the Company, said, "The 2023 fiscal results are very encouraging; we posted the highest revenue in the company's history, and the company had positive cash flow from operating activities.

Spectrum Dynamics is proud to announce the Installation of the VERITON-CT SPECT/CT imaging system at European Leading Cancer Center, Gustave Roussy

Retrieved on: 
Thursday, March 21, 2024
Toxicity, CZT, Algorithm, Patient, Neoplasm, Hospital, 3D, Cancer, Gustave Roussy, Google Images, The, SPECT, SPECT/CT, Newsweek, Nuclear medicine, Health, Medical imaging

Gustave Roussy is considered as a leading cancer centre in Europe.

Key Points: 
  • Gustave Roussy is considered as a leading cancer centre in Europe.
  • The institute treats patients with all types of cancer at any age and is a leading institution in the treatment of rare and complex tumors.
  • It is unlike any other ring-shaped gantry, with a 360o CZT 12-detector design that automatically moves close to the patient's body.
  • "We are delighted to collaborate with Gustav Roussy with the install of the VERITON-CT 400 SPECT/CT scanner," says Johann Fernando, Executive Vice President, Spectrum Dynamics.

QDOSE® Platform Partnership for Personalised Dosimetry in Radiopharmaceutical Therapy

Retrieved on: 
Monday, March 18, 2024
Radiation, CE, ASX, European, TLX, FDA, Nuclear medicine, Medical imaging

QDOSE® is a validated, versatile software platform that enables reliable estimation of patient-specific dosimetry for both therapeutic and diagnostic radiopharmaceuticals.

Key Points: 
  • QDOSE® is a validated, versatile software platform that enables reliable estimation of patient-specific dosimetry for both therapeutic and diagnostic radiopharmaceuticals.
  • Telix intends to integrate the QDOSE® platform into its therapeutic radiopharmaceutical programs and clinical collaborations to enable the development of personalised treatment regimens.
  • Personalised radiopharmaceutical therapy administration based on individual patient dosimetry has the potential to improve clinical outcomes by optimising treatment response while reducing effects on normal healthy organs and optimising the use of isotope supply chains.
  • Rapid, reliable and personalised dosimetry is becoming an increasingly important future direction of cancer care and regulatory authorities now expect to see dosimetry analysis.

Curium Announces First Commercial Doses in Italy of PYLCLARI® – An Innovative 18F-PSMA PET Tracer Indicated in Patients With Prostate Cancer

Retrieved on: 
Thursday, March 7, 2024
Curium, European Commission, Physician, FDA, Food, PSMA, Prostate, INN, European, Civil service commission, Patient, Nuclear medicine, PET, Cancer, Prostate cancer, Medical imaging

PARIS, March 07, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that the first commercial doses of PYLCLARI® have been sold in Italy.

Key Points: 
  • PARIS, March 07, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that the first commercial doses of PYLCLARI® have been sold in Italy.
  • Today’s announcement follows the decision in July 2023 by the European Commission granting marketing authorization for PYLCLARI® in the European Union.
  • On 3rd February 2024 The Italian Medicines Agency (Agenzia Italiana del Farmaco) published the decision for PYLCLARI® in Italy.
  • The European rights were licensed by Curium from Progenics, a Lantheus company, in 2018.

Curium Announces Submission of the Marketing Authorization Application for PYLCLARI®, an Innovative (18F)-PSMA PET Tracer Indicated in Adults With Prostate Cancer to Swissmedic

Retrieved on: 
Thursday, February 22, 2024
Radiopharmaceutical, European Commission, SPECT, Physician, Marketing, FDA, Food, Cancer, PSMA, Agency, INN, Death, Civil service commission, European Medicines Agency, AG, Patient, Nuclear medicine, Prostate cancer, Diagnosis, PCA, PET, Medical imaging

Dr. Michel Wuillemin, Head of Radiopharmaceuticals at b.e.imaging, commented, “b.e.Imaging is proud of the submission of the marketing authorization application for PYLCLARI® to Swissmedic ahead of schedule.

Key Points: 
  • Dr. Michel Wuillemin, Head of Radiopharmaceuticals at b.e.imaging, commented, “b.e.Imaging is proud of the submission of the marketing authorization application for PYLCLARI® to Swissmedic ahead of schedule.
  • We are fully dedicated to improving the situation of prostate cancer patients in Switzerland.”
    Benoit Woessmer, PET Europe CEO at Curium, commented, “The acceptance of the marketing authorization application by Swissmedic for PYLCLARI® is another important milestone for prostate cancer patients in Switzerland.
  • We look forward to providing an improved choice of tools available to physicians for the diagnosis of prostate cancer patients.
  • Marketing authorization for PYLCLARI® (also known as (18F)-DCFPyL) was granted in July 2023 by the European Commission.

Roha Medical Campus, a World-Class Hospital in Ethiopia, Gets $42 Million First Injection

Retrieved on: 
Thursday, February 22, 2024
Hospitals, Finance, Banking, Professional Services, Public Policy, Government, Healthcare Reform, Transportation, General Health, Health, Travel, Stroke, Diabetes, Cancer, Hospital, Economic development, Neurosurgery, Spine, Research, Flood, Physician, Respiratory failure, Quality of life, Death, African Union, Medical tourism, Urbanization, Emergency, Elective surgery, Carbon, RMC, Vaccination, Health care, Tree, International airport, Patient, Teaching, Nuclear medicine, African, Map, Tuberculosis, Infection, Mortality, HIV, Notifiable disease, Environment

The equity funding represents the first tranche of a US$130 million investment to build phase 1 of Roha Medical Campus, a 350-bed world-class hospital.

Key Points: 
  • The equity funding represents the first tranche of a US$130 million investment to build phase 1 of Roha Medical Campus, a 350-bed world-class hospital.
  • Designed to be Ethiopia’s first JCI-accredited1 hospital, Roha Medical Campus will alleviate an acute shortage of advanced medical facilities and healthcare services for Africa’s second largest nation and patients in the region.
  • “Ethiopian Airlines’ global connectivity strengthens the case for medical tourism and ensures strong US dollar revenue for the hospital.
  • Roha Medical Campus will reduce costs and increase accessibility relative to other local hospitals and comparable international medical tourism packages.

Blue Earth Therapeutics Announces Publication of Results from Independent Clinical Experience with 177Lu-rhPSMA-10.1 in Treatment of Metastatic Castrate Resistant Prostate Cancer

Retrieved on: 
Tuesday, February 20, 2024
Science, Radiology, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Therapeutic index, DOI, Nuclear medicine, Prostate cancer, Neoplasm, Isotope, Teaching hospital, Physician, Safety, Food, PSMA, Treatment, Hope, Manuscript, Therapy, Patient, Optimism, Journal, PSA, Legislation, Prostate-specific antigen, Metastasis, Medical imaging

The manuscript, “First Safety and Efficacy Data with the Radiohybrid 177Lu-rhPSMA-10.1 for the Treatment of Metastatic Prostate Cancer,” has been published in the Journal of Nuclear Medicine (DOI https://doi.org/10.2967/jnumed.123.266741 ).

Key Points: 
  • The manuscript, “First Safety and Efficacy Data with the Radiohybrid 177Lu-rhPSMA-10.1 for the Treatment of Metastatic Prostate Cancer,” has been published in the Journal of Nuclear Medicine (DOI https://doi.org/10.2967/jnumed.123.266741 ).
  • In the 4 consecutive patients with metastatic prostate cancer who were evaluated, when looking at radiologic progression free survival (rPFS), 2 patients had not progressed at 24 and 18 months of follow-up.
  • 177Lu-rhPSMA-10.1 is an investigational radiohybrid (rh) Prostate-Specific Membrane Antigen-targeted radiopharmaceutical for the treatment of prostate cancer, and the lead candidate in Blue Earth Therapeutics’ development of next generation therapeutic radiopharmaceuticals.
  • “These promising clinical data give us further optimism in advancing 177Lu-rhPSMA forward in clinical development, with the hope to help treat patients with metastatic prostate cancer.

Serving Patients and Communities Through Comprehensive Care Solutions: OSF HealthCare, Pointcore, Inc. and GE HealthCare Enter Strategic Care Alliance

Retrieved on: 
Monday, February 19, 2024
Health Technology, Telemedicine, Virtual Medicine, Data Management, Other Health, Technology, Pharmaceutical, Practice Management, Managed Care, General Health, Hospitals, Other Technology, Biotechnology, Software, Networks, Health, Love, Hospital, Mission, OSF HealthCare, Multimedia, Prostate cancer, Missionary, FDA, Radiology, OSF, Patient, Nuclear medicine, Knowledge, GE HealthCare, Radiation, MRI, Equipment manager

It will also support the Mission of OSF HealthCare to deliver exceptional care to patients in the communities they serve.

Key Points: 
  • It will also support the Mission of OSF HealthCare to deliver exceptional care to patients in the communities they serve.
  • OSF HealthCare, Pointcore and GE HealthCare expect to explore ways to scale their approach to drive greater access to personalized care for more patients.
  • The alliance will concentrate on enhancing precision care in oncology by identifying clinical and technological opportunities that can help accelerate integrated cancer care at OSF HealthCare.
  • “OSF HealthCare, Pointcore and GE HealthCare are doing this together through integrated technology, digital solutions, advanced analytics and dedicated clinical and operational specialists.

ICPO Foundation and SBMN Enter Strategic Partnership to Promote International Education Standards and Training Support in Brazil

Retrieved on: 
Tuesday, February 20, 2024
Health Technology, Technology, Continuing, Radiology, Education, Training, Oncology, Hospitals, Clinical Trials, Other Technology, Science, Biotechnology, Nursing, Health, Research, Therapy, Hospital, Multimedia, Physician, Curriculum, RPO, Medicine, Certification, To Brazil!, Patient, Nuclear medicine, ICPO, Cancer, Partnership

View the full release here: https://www.businesswire.com/news/home/20240219353852/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240219353852/en/
    ICPO Foundation and SBMN enter strategic partnership to promote international education standards and training support in Brazil.
  • As part of this collaboration, ICPO and SBMN will work to revolutionize Radiomolecular Precision Oncology in Brazil, with a focus on elevating patient care, education, and research on a global scale.
  • Practical training sessions will also be conducted in Brazil at carefully selected ICPO Collaborating Centers, in a collaborative effort between SBMN and ICPO.
  • ICPO will also formulate the fundamental certification path for the ICPO Academy and the practical training curriculum in collaboration with ICPO Collaborating Centers, with SBMN providing essential support in Brazil.

Industry Leaders Announce the Cardiac PET Industry Coalition (CPIC)

Retrieved on: 
Tuesday, March 5, 2024
Marketing, Coalition, Nuclear medicine, Multimedia, CMS, Cardiovascular disease, Human, Medicare, CPIC, Health, Patient, Policy, Heart, Bracco (company), Congress, Molecular imaging, Siemens Healthineers, PET, Medical imaging

WILMINGTON, Del., March 5, 2024 /PRNewswire-PRWeb/ -- Leading manufacturers in cardiac positron emission tomography (PET) imaging launched the Cardiac PET Industry Coalition (CPIC), an initiative dedicated to promoting federal policies that advance health outcomes for patients with cardiovascular disease and the availability of cardiac PET diagnostics. CPIC will champion fair and transparent coverage and reimbursement policies that facilitate access to cardiac PET, align practitioners with regard to research opportunities, highlight the clinical and economic benefit of this modality, and provide expanded opportunities to educate healthcare providers and policymakers on the overall value of cardiac PET.

Key Points: 
  • WILMINGTON, Del., March 5, 2024 /PRNewswire-PRWeb/ -- Leading manufacturers in cardiac positron emission tomography (PET) imaging launched the Cardiac PET Industry Coalition (CPIC) , an initiative dedicated to promoting federal policies that advance health outcomes for patients with cardiovascular disease and the availability of cardiac PET diagnostics.
  • "The clinical benefits of cardiac PET imaging are well-documented for making patient care and treatment decisions.
  • "I'm proud of the work the Coalition is doing to increase awareness, maintain appropriate reimbursement and expand the adoption of cardiac PET imaging."
  • Phil Cranmer, Cardiac PET Industry Coalition (CPIC), 1 (215) 888-0040, [email protected] , https://cpicoalition.com/
    View original content to download multimedia: https://www.prweb.com/releases/industry-leaders-announce-the-cardiac-pet...